Table 1.

Correlation of onset of antiviral treatment and antigenemia, viremia, and L-DNAemia level in solid-organ transplant patients with primary HCMV infection

PatientType of transplantSexaAge (yr)Days after transplantHCMV quantitation in bloodAntiviral drug (days of administration)bOnset of treatment after 1st positive antigenemia (day)HCMV-related clinical symptomsc
ViremiaAntigenemiaL-DNAemia
5HTM373000
10000
170010
240012
2835147
314261,122
33155127>10,000
35184390>10,000G (35–48)7+
38085114
40025185
420610
4701NDd
10HTM182000
90011
160018
183217562
2303379
262353ND
30ND1421,995G (31–44)13+
37010251
400020
12HTM2716000
190419
2670180194
30136400>10,000
33110300>10,000F (34–48)15+
37035
16SLTM46200010
2308208
2530125316G (25–33)2
270323225
300400141
325390105
343360101F (34–47)
3601011
39055
410012
44000
22SLTF2420000
25ND1310
3206637G (26–41)1
350109256
390235
41085
50015
55005
26HTM3021000
28000
33005
3555141
40028742G (36–57)1
470225
54025
57000
  • a M, male; F, female.

  • b G, ganciclovir; F, foscarnet.

  • c +, presence of clinical symptoms; −, absence of clinical symptoms.

  • d ND, not determined.